Article Sidebar
Published:
Nov 13, 2020DOI:
10.4314/tjpr.v19i6.1Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Formulation and development of a topical combination cream for arthritis management
Abstract
Purpose: To design and prepare a non-prescription cream for cost-effective, potent, rapid and longlasting relief from arthritic pain.
Method: The cream was prepared by formulating the aqueous phase using glucosamine sulphate, potassium chloride and chondroitin sulphate sodium, and then pouring it into the oil phase under suitable conditions. The physicochemical and antimicrobial properties, in vitro and ex vivo drug release, and overall physical and chemical stability of the formulations were characterized.
Results: Sodium metabisulfite (0.5 %) and butylated hydroxyanisole (BHA) (0.01 %) showed a very strong synergistic effect on overall stability of the cream.
Conclusion: This study confirms that the formulated cream is potentially suitable for the management of arthritis pain in patients.
Keywords: Arthritis, Ex vivo drug release, Sodium metabisulfite, Butylated hydroxyanisole, Product stability
